Gene Therapy With URO-902 (pVAX/) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial.

Purpose: To assess efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca-activated K channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB).

Materials And Methods: Women, 40‒79 years, with OAB and urge urinary incontinence (UUI) who were refractory to OAB medications were randomized to single-dose URO-902 24 and 48 mg or placebo administered by intradetrusor injection via cystoscopy under local anesthesia. Efficacy endpoints included change from baseline to week 12 in mean daily micturitions, urgency episodes, UUI episodes, and patient-reported outcomes.

The GPR39 Receptor Plays an Important Role in the Pathogenesis of Overactive Bladder and Corticosterone-Induced Depression.

Despite the close and clinically confirmed association between depression and overactive bladder, it remains unclear whether this affective disorder is a factor causing overactive bladder or whether overactive bladder is a specific symptom of psychosomatic disorders. This study examined the effects of repeated corticosterone administration on the occurrence of symptoms associated with depression and overactive bladder. Additionally, we examined whether administering TC-G 1008, an antidepressant that selectively activates the GPR39 receptor, could alleviate corticosterone-induced depression-like behavior and detrusor overactivity-related changes in cystometric measurements.

A Five-Year Retrospective Study on the Clinical Outcomes of Sacral Nerve Stimulation for Neuromodulation of the Lower Urinary Tract in a Tertiary Hospital.

Aim: To assess clinical outcomes in terms of first to second-stage conversion rates, revision rates, and complications for all patients undergoing sacral neuromodulation of the lower urinary tract for the past five years at the Queen Elizabeth Hospital Birmingham.

Method: This is a retrospective observational study. Only patients with the first stage of sacral neuromodulation between January 2017 and January 2023 were included in the study.

Deterioration of cystometric parameters following the artificial urinary sphincter procedure in patients with spinal cord lesion: a retrospective analysis.

Purpose: The artificial urinary sphincter (AUS) remains the gold standard to treat stress urinary incontinence related to sphincter insufficiency in patients with neurogenic lower urinary tract dysfunction (NLUTD). This study aims to assess the incidence of de novo neurogenic detrusor overactivity or low bladder compliance after AUS implantation in adult spinal cord injured patients.

Methods: Retrospective observational study, descriptive by analysis of the medical records of patients followed in a department of Neuro-Urology from January 01, 2003 to March 31, 2023.

Patient Persistence to OnabotulinumtoxinA Treatment for Overactive Bladder Using a Reduced Injection-Site Paradigm: A Retrospective Chart Review Study.

Aims: OnabotulinumtoxinA (onabotA) is an approved treatment for overactive bladder (OAB). This chart review study aims to determine treatment persistence in patients receiving onabotA (100 U) via a reduced injection-site paradigm distributed across ≤ 3 injection sites.

Methods: This study was a single site, noninterventional, retrospective chart review evaluating adult female OAB patients refractory to behavioral modification and pharmacotherapy before receiving ≥ 1 treatment with onabotA (100 U) via 1-3 injections between July 2017 and June 2021.

Effectiveness and Safety Profile of Urethral Bulking with Bulkamid for Stress Urinary Incontinence: A French Multi-Center Cohort Study.

Introduction And Hypothesis: Various treatment options are currently available for the management of stress urinary incontinence (SUI). This study was aimed at determining the effectiveness and safety profile of Bulkamid, and identify predictive factors of clinical success.

Methods: This retrospective study conducted in two French urogynecology university centers between September 2019 and December 2023 included all patients with urinary incontinence who received Bulkamid.

Artificial urinary sphincter implantation after transperineal open reconstruction of post-prostatectomy vesicourethral anastomotic stenosis.

Purpose: This study evaluates the effectiveness of artificial urinary sphincter (AUS) implantation following transperineal reanastomosis in men with vesicourethral anastomotic stenosis (VUAS) and stress urinary incontinence (SUI) after radical prostatectomy (RP), focusing on long-term explantation rates and urinary continence.

Methods: Patients treated between 2009 and 2020 were retrospectively analyzed. Those undergoing AUS implantation post-transperineal reanastomosis for recurrent VUAS, excluding cases with prior pelvic irradiation and overactive bladder, were included.

The mechanism of action of neuromodulation in the treatment of overactive bladder.

Neuromodulation has been used in the treatment of various pelvic organ dysfunctions for almost 40 years and several placebo-controlled studies have confirmed its clinical effect. Many neuromodulation methods using different devices and stimulation parameters, targeting different neural structures have been introduced, but only a limited number have been adopted into routine clinical use. A substantial volume of basic research and clinical studies addressing specific effects of neuromodulation in the treatment of overactive bladder (OAB) have been published to date; however, their mechanistic implications have not been comprehensively summarized.

Evolution of the medium-term functional outcomes of holmium laser prostate enucleation (HoLEP).

Introduction: The boom in surgery for benign prostatic hyperplasia using Holmium laser enucleation (HoLEP) has reduced length of hospitalization, catheterization duration and the risk of bleeding, with comparable results to the old gold standard. The aim of this study is to evaluate the evolution of medium-term functional results after HoLEP.

Method: Retrospective monocentric observational study in patients who underwent HoLEP surgery from 2014 to 2019.

Transcutaneous Tibial Nerve Stimulation for Urge Incontinence: A Randomized Clinical Trial.

Importance: Overactive bladder is a distressing syndrome that significantly affects quality of life. Transcutaneous tibial nerve stimulation (TTNS) has been proposed as a home-based, patient-centered therapy that could improve access to treatment for this condition.

Objective: We aimed to determine the efficacy of 12 weeks of TTNS versus sham therapy in reducing symptomatic bother in ambulatory women with urgency urinary incontinence.

Outpatient Periurethral Injections of Polyacrylamide Hydrogel (Bulkamid) Under Local Anesthesia in the Office: A Prospective Single-center Series.

Objective: To report our experience of outpatient periurethral injections of Bulkamid under local anesthesia in the office in female patients for stress urinary incontinence (SUI). Polyacrylamide hydrogel (Bulkamid) is a relatively recent bulking agent which may have a better safety profile than previous generations.

Methods: The data of all women who underwent outpatient periurethral Bulkamid injections under local anesthesia in the office at a single academic center were collected prospectively between November 2019 and August 2023.

[Overactive bladder in the elderly].

Overactive bladder (OAB) is a syndrome consisting of urgency, usually accompanied by urinary frequency and nocturia, with or without urgent incontinence, in absence of a causative infection or pathological conditions. The prevalence of OAB is approximately 11-19% in both men and women, and leads to a significant negative effect on health-related quality of life. The prevalence of OAB increases with age.

[Efficacy and safety of the polypeptide drug Vesusten in the correction of neurogenic LUTS in Multiple Sclerosis. Results of the pilot study].

Objective: The purpose of this study was to evaluate the effectiveness of the drugs Solifenacin and Vesusten in relation to the treatment of neurogenic bladder overactivity in multiple sclerosis (MS).

Materials And Methods: A prospective, single-site, single-center, placebo-controlled, parallel-group, comparative clinical trial was conducted. The study included 41 MS patients of both sexes aged 18-50 years with urodynamically confirmed detrusor overactivity.

[Bioregulatory therapy for overactive bladder].

This review is devoted to the pathogenetic basis and clinical results of the use of a new domestic innovative drug Vesusten, which is based on polypeptides made of animal bladder tissue, for the treatment of patients with overactive bladder. Data are given regarding the epidemiology, pathogenesis factors and current treatment methods. The mechanisms of peptide regulation of physiological processes in humans are also described.